ANTIBODIES DERIVED FROM DYAX LIBRARY ENTER CLINICAL TRIALS AT IMCLONE SYSTEMS

Dyax has announced that two fully human monoclonal antibodies that were derived from Dyax's proprietary phage display libraries have entered into Phase I clinical development at ImClone Systems, as recently reported by the Dyax library licensee.

ImClone Systems reported that the antibodies, IMC-11F8 and IMC-1121B, both of which target growth factor receptors, are being evaluated for their potential as cancer therapeutics. Each antibody was isolated by ImClone Systems using an antibody-fragment (Fab) phage display library licensed to the company by Dyax, and then further optimized by ImClone Systems.